[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"b-cell-lymphoblastic-leukemialymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:b-cell-lymphoblastic-leukemialymphoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100625415","a-multi-site-study-to-evaluate-the-persistence-of-protective-immunity-to-routine-childhood-vaccinations-in-participants-with-b-allly-who-have-received-blinatumomab-100625415",false,"NCT07422337","A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL\u002FLy Who Have Received Blinatumomab","Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination","BOOSTER","Inclusion Criteria:\n\n* Diagnosis of B-lineage acute lymphoblastic leukemia\u002Flymphoma\n* ≥1 year old and up to 21 years old at diagnosis\n* Informed consent provided, and if applicable, child assent provided\n* Must have received all vaccinations routinely administered during first year of life\n\nExclusion Criteria:\n\n* Relapsed\u002Frefractory disease at any time\n* Received or will require a bone marrow transplant and\u002For cellular therapy\n* Pregnancy","ALL","1 Year","23 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia\u002FLymphoma. The main study aims are:\n\n* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL\u002FLy who have received blinatumomab.\n* To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity.\n\nResearchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.",[26,27,28,29,30,31,32,33],"B-Cell ALL","B-Cell Acute Lymphoblastic Leukaemia","B-Cell Lymphoblastic Leukemia","B-Cell Lymphoblastic Leukemia\u002FLymphoma","B-cell Acute Lymphoblastic Leukemia (B-ALL)","B-cell Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","B-cell Leukemia",[35,36,37,38],"vaccines","cancer","blinatumomab","immunotherapy","RECRUITING","2026-02-23",{"date":42,"type":43},"2026-02-25","ACTUAL",{"date":45,"type":43},"2026-01-13",{"date":47,"type":22},"2029-01",{"name":49,"class":50},"Arkansas Children's Hospital Research Institute","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100572609","phase-1-cd19--cd22-bispecific-car-t-cells-in-the-treatment-of-relapsedrefractory-b-cell-hematologic-tumors-100572609","NCT06735495","CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed\u002FRefractory B Cell Hematologic Tumors","The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed \u002F Refractory B Cell Hematological Tumors","Inclusion Criteria:\n\n1.CD 19 + \u002F CD 22 + B cell hematological tumor was confirmed by pathological and histological examination, and the patient met the following criteria for relapsed or refractory B cell hematological tumor:\n\n1. Refractory \u002F relapsed B lymphocytic leukemia (1 of the following 4 items can be met):\n\n   i . Recurrence within 6 months of first remission; ii. Primary refractory without complete remission after 2 cycles of standard chemotherapy regimen; iii. No complete remission or recurrence after first-line or multiline salvage chemotherapy; iv. Not eligible for HSCT conditions, abandonment of HSCT, or relapse after HSCT due to conditional limitations.\n2. Refractory \u002F relapsed B-cell lymphoma (meet the following item 1 of the first 4 items plus item 5):\n\ni . After four courses of chemotherapy with a standard regimen, tumor shrinkage was less than 50% or disease progression; ii . CR after standard regimen chemotherapy, but relapsed within 6 months; iii.2 or more recurrences after CR; iv . Not suitable for hematopoietic stem cell transplantation, or abandoning HSCT due to conditional restrictions or relapse after hematopoietic stem cell transplantation; v . Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20 and combination chemotherapy containing an anthracycline drug agent.\n\n2.The results of FCM or immunohistochemical detection of tumor antigen (CD 19 \u002F CD 22) were positive.\n\n3.The estimated survival period is more than 3 months starting from the signing of the informed consent form.\n\n4.Good organ function,Meet the following requirements：\n\n1. HGB≥70g\u002FL(transfusible)\n2. Liver and kidney function: creatinine ≤1.5XULN: total bilirubin ≤1.5XULN:ALT and AST≤2.5X ULN\n3. Cardiopulmonary function: left ventricular ejection fraction \\>50%; Blood oxygen saturation \\>90%;\n\n5.Subjects with the Eastern Cooperative Oncology Group (ECOG) fitness scores of 0 to 2.\n\nExclusion Criteria：(If meet any of the following criteria, patients will not be included)\n\n1. Serious heart insufficiency,LVEF \\\u003C50%\n2. History of severe pulmonary function impairment disease.\n3. Other malignant tumors in the advanced stage.\n4. Severe infection or persistent infection that cannot be effectively controlled.\n5. Combined with severe autoimmune disease or innate immune deficiency.\n6. Active hepatitis (hepatitis B virus deoxyribonucleic acid \\[HBV-DNA 500 IU \u002F ml and abnormal liver function\\] or hepatitis C antibody \\[HCV-Ab\\] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function).\n7. Human immunodeficiency virus (HIV) infection or syphilis infection.\n8. History of severe allergies to biological products (including antibiotics).\n9. Acute graft-versus-host response (GVHD) allogeneic hematopoietic stem remained one month after immunosuppressant discontinuation.\n10. Patients who have other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the clinical trial or interfere with the study results, and who are deemed unsuitable for participation in the clinical trial by the investigator","3 Years","75 Years",{"count":62,"type":22},80,"INTERVENTIONAL",[65,66],"PHASE1","PHASE2","This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed \u002F refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \\& CD22 bispecific CAR-T cells in relapsed \u002F refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.",[29],[70,71,72],"CAR-T","dual-target","Relapsed \u002F Refractory B Cell Hematological Tumors","2024-12-10",{"date":75,"type":43},"2024-12-16",{"date":77,"type":43},"2024-11-04",{"date":79,"type":22},"2027-12-31",{"name":81,"class":50},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":60,"enrollmentInfo":91,"targetDuration":4,"studyType":63,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":82},"100554746","phase-1-cd19--cd20-bispecific-car-t-cells-for-relapsed--refractory-b-cell-hematological-tumors-100554746","NCT06503094","CD19 & CD20 Bispecific CAR T Cells for Relapsed \u002F Refractory B Cell Hematological Tumors","The Safety and Efficacy of CD19 & CD20 Bispecific CAR T Cells in Treating Relapsed \u002F Refractory B Cell Hematological Tumors","Inclusion Criteria:\n\n* Fully understand and voluntarily sign the informed consent form, and be willing and able to comply with the visit, treatment protocol, laboratory tests, and other study requirements specified in the flow sheet;\n* CD 19 + \u002F CD 20 + B cell hematological tumor was confirmed by pathological and histological examination, and the patient met the following criteria for relapsed or refractory B cell hematological tumor:\n\n  1. Refractory \u002F relapsed B lymphocytic leukemia (1 of the following 4 items can be met):\n\n     i . Recurrence within 6 months of first remission; ii. Primary refractory without complete remission after 2 cycles of standard chemotherapy regimen; iii. No complete remission or recurrence after first-line or multiline salvage chemotherapy; iv. Not eligible for HSCT conditions, abandonment of HSCT, or relapse after HSCT due to conditional limitations.\n  2. Refractory \u002F relapsed B-cell lymphoma (meet the following item 1 of the first 4 items plus item 5):\n\ni . After four courses of chemotherapy with a standard regimen, tumor shrinkage was less than 50% or disease progression; ii . CR after standard regimen chemotherapy, but relapsed within 6 months; iii.2 or more recurrences after CR; iv . Not suitable for hematopoietic stem cell transplantation, or abandoning HSCT due to conditional restrictions or relapse after hematopoietic stem cell transplantation; v . Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20 and combination chemotherapy containing an anthracycline drug agent.\n\n* B-cell hematological tumors include the following 3 categories:\n\n  1. B-cell acute lymphoblastic leukemia (B-ALL);\n  2. Indolent B-cell lymphoma (CLL, FL, MZL, LPL, HCL);\n  3. Invasive B-cell lymphoma (DLBCL, BL, and MCL);\n* With measurable or evaluable lesions: Lymphoma patients require a single lesion 15mm or 2 or more lesions 10mm; patients with leukemia require persistent positive or positive recurrence of bone marrow MRD.\n* Subjects with the Eastern Cooperative Oncology Group (ECOG) fitness scores of 0 to 2.\n* The results of FCM or immunohistochemical detection of tumor antigen (CD 19 \u002F CD 20) were positive.\n* The estimated survival period is more than 3 months starting from the signing of the informed consent form.\n\nExclusion Criteria:\n\n* Appearance of one of the following cardiac criteria: atrial fibrillation; myocardial infarction in the last 12 months; prolonged QT syndrome or secondary QT extension, as judged by the investigator. Echocardiography LVSF \\\u003C30% or LVEF \\\u003C50%; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV (confirmed by echocardiography within 12 months of treatment).\n* Active GVHD.\n* History of severe pulmonary function impairment disease.\n* Other malignant tumors in the advanced stage.\n* Severe infection or persistent infection that cannot be effectively controlled.\n* Combined with severe autoimmune disease or innate immune deficiency.\n* Active hepatitis (hepatitis B virus deoxyribonucleic acid \\[HBV-DNA 500 IU \u002F ml and abnormal liver function\\] or hepatitis C antibody \\[HCV-Ab\\] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function).\n* Human immunodeficiency virus (HIV) infection or syphilis infection.\n* History of severe allergies to biological products (including antibiotics).\n* There are central nervous system disorders, such as uncontrolled epilepsy, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar diseases, etc..\n* Female patients are in pregnancy and lactation, or have a pregnancy plan within 12 months.\n* situations where the investigator may increase the risk or interfere with the test results.","14 Years",{"count":62,"type":22},[65,66],"This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed \u002F refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \\& CD20 bispecific CAR-T cells in relapsed \u002F refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.",[29],[70,71,72],"2024-07-09",{"date":98,"type":43},"2024-07-16",{"date":100,"type":43},"2024-01-14",{"date":102,"type":22},"2026-06-18",{"name":81,"class":50}]